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Background: Gleason pattern 3 less often has molecular abnormalities and often behaves indolent. It is
controversial whether low grade small foci of prostate cancer (PCa) on biopsy could avoid immediate treatment or
not, because substantial cases harbor unfavorable pathologic results on prostatectomy specimens. This study was
designed to identify clinical predictors for classical and redefined insignificant cancer on prostatectomy specimens
in Japanese men with favorable pathologic features on biopsy.
Methods: Retrospective review of 1040 PCa Japanese patients underwent radical prostatectomy between 2006
and 2013. Of those, 170 patients (16.3%) met the inclusion criteria of clinical stage ≤ cT2a, Gleason score (GS) ≤ 6,
up to two positive biopsies, and no more than 50% of cancer involvement in any core. The associations between
preoperative data and unfavorable pathologic results of prostatectomy specimens, and oncological outcome were
analyzed. The definition of insignificant cancer consisted of pathologic stage ≤ pT2, GS ≤ 6, and an index tumor
volume < 0.5 mL (classical) or 1.3 mL (redefined).
Results: Pathologic stage ≥ pT3, upgraded GS, index tumor volume ≥ 0.5 mL, and ≥ 1.3 mL were detected in 25
(14.7%), 77 (45.3%), 83 (48.8%), and 53 patients (31.2%), respectively. Less than half of cases had classical (41.2%) and
redefined (47.6%) insignificant cancer. The 5-year recurrence-free survival was 86.8%, and the insignificant cancers
essentially did not relapse regardless of the surgical margin status. MRI-estimated prostate volume, tumor length on
biopsy, prostate-specific antigen density (PSAD), and findings of magnetic resonance imaging were associated with
the presence of classical and redefined insignificant cancer. Large prostate volume and short tumor length on
biopsy remained as independent predictors in multivariate analysis.
Conclusions: Favorable features of biopsy often are followed by adverse pathologic findings on prostatectomy
specimens despite fulfilling the established criteria. The finding that prostate volume is important does not simply
mirror many other studies showing PSAD is important, and the clinical criteria for risk assessment before definitive
therapy or active surveillance should incorporate these significant factors other than clinical T-staging or PSAD to
minimize under-estimation of cancer in Japanese patients with low-risk PCa.
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The widespread use of prostate-specific antigen (PSA)
screening and multiple core biopsy protocol resulted in
early detection of prostate cancer (PCa) at a curable
stage, and was associated with dramatic decrease in PCa
mortality in North America and Europe [1]. The Euro-
pean Randomized Study of Screening for Prostate Can-
cer (ERSPC) trial showed that PSA-based screening
significantly reduced mortality by 21% [2]. The analysis
of cancer trends using the national cancer mortality data
in Japan also revealed the similar stage migration of
PCa. The incidence of localized cancer increased mark-
edly between 2000 and 2003 with an annual percent
change of 29.7%, then became stable, while PCa mortal-
ity began to decrease in 2004 [3]. The early detection of
PCa consequently raises the new issue that the propor-
tion of low-risk cancers for which the definitive therapy
will not alter prognosis has been increasing. Potential
side effects after definitive therapies for localized cancer
worsen the patients’ quality of life [4], even with the
current advantages of robot-assisted surgery or image-
guided radiation therapy.
Gleason pattern 3 less often has molecular abnormalities,
so called cancer hallmarks and often behaves indolent com-
pared to Gleason pattern 4 in PCa [5,6]. Although all pa-
tients underwent prostatectomy and it was uncertain how
therapeutic an effect it had, the 15-year cancer specific mor-
tality rate for pathologic Gleason score (GS) 6 or less was
reported as 0.2% [7]. On the other hand, it is controversial
whether the low grade and low volume PCa within a few
positive biopsy cores could avoid immediate definitive ther-
apy or not, because some cases harbor unfavorable patho-
logic features at radical prostatectomy specimens with a
variety of rates [8]. To predict clinically insignificant cancer
in patients with clinical T1c (non-palpable) PCa, Epstein
et al. reported a set of criteria [9], and later updated to the
contemporary version, including PSA density < 0.15 ng/mL,
biopsy Gleason score ≤ 6, the presence of tumor in two or
fewer cores, and no more than 50% involvement by tumor
in any core [10]. The review of validation studies on Epstein
criteria concluded that it had suboptimal accuracy for pre-
dicting insignificant cancer from significant heterogeneity
in the results of insignificant cancer, GS ≤ 6, and organ-
confined status at 37–76%, 54.3–75.9% and 80.0–96.9%,
respectively [11]. Currently, active surveillance (AS) has
become one of the key treatment options as a strategy for
deferring treatment for low-risk PCa in American and
European urological associations’ guidelines, but the pres-
ence of several AS protocols consisting of different clinic-
pathologic factors complicate decision making of physicians
and patients.
In view of the racial differences, the clinical criteria devel-
oped from Western cohort analysis could not be directly
applied to Japanese or Asian patients [12]. In addition, theupdated definition of index tumor volume threshold to
1.3 mL and total tumor volume threshold to 2.5 mL for in-
significant cancer raises reconsideration of the current risk
assessment before therapy [13]. To our knowledge, the
study using this updated definition has still been insuffi-
cient. In this study, we investigated the associations be-
tween preoperative clinical data and pathologic results of
prostatectomy specimens along with oncological outcome
to identify predictors for classical and redefined insignifi-
cant cancer in Japanese men who met our expanded inclu-
sion criteria.
Methods
Inclusion criteria of patients
The study population consisted of 1040 consecutive pa-
tients that underwent radical prostatectomy between
January 2006 and December 2013 at 2 Japanese academic
institutions. We retrospectively reviewed the records for
those pathologic findings of multiple core biopsy and clin-
ical stages. Of those, 170 patients met our inclusion cri-
teria of clinical stage ≤ cT2a [14], GS ≤ 6 without Gleason
pattern 4 or 5 as secondary scores, up to two biopsies with
cancer, and no more than 50% of cancer involvement in
any core; no limitation was set on PSA value and PSA
density (PSAD). None of the patients had received hor-
monal treatments including antiandrogens, luteinizing
hormone-releasing hormone analogues, or 5-alpha re-
ductase inhibitors preoperatively.
Preoperative clinical data including biopsy and
radiographic image
Preoperative patient characteristics are provided in
Table 1; All prostate volume was measured by magnetic
resonance imaging (MRI), which was more accurate than
transrectal ultrasound and computed tomography for
volume estimation [15], and PSAD was determined as
pre-biopsy PSA value divided by MRI-estimated prostate
volume. The mean number of biopsy cores per proced-
ure was 13.1 and 19 cases (11.2%) had fewer than 10
cores. Biopsy specimens obtained by transrectal and
transperineal approaches were evaluated for GS, number
of cores involved with cancer, total length of tissue, and
length of cancer measured with subtracting the interven-
ing benign glands. Gleason scoring of the biopsy speci-
mens was done according to the International Society of
Urological Pathology (ISUP) Consensus 2005; the second
most prevalent pattern to the highest cancer grade ob-
servable in the specimen [16]. MRI findings were simply
classified according to report by radiologists whether
there were typical suspicious lesions for malignancy or
not. Seventy patients (41.2%) fulfilled the contemporary
Epstein criteria [10], and 103 patients (60.6%) fulfilled
the criteria of the Prostate Cancer Research Inter-
national: Active Surveillance (PRIAS) study [17]. The
Table 1 Preoperative patient characteristic
Number (%) or Mean value (range)
Number 170 (100)
Age (year) 65.5 (40 to 78)
PSA (ng/ml) 7.4 (2.8 to 25.9)
Prostate volume (cc) 40.2 (13.8 to 87.9)
PSA density (ng/ml/cc) 0.208 (0.050 to 1.124)
Biospy core (n) 13.1 (6 to 24)






















Abbreviations: DRE dicital rectal examination, PRIAS Prostate Cancer Research
International: Active Surveillance.
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mL, PSAD <0.2 ng/ml/cc, ≤2 positive cores, and GS ≤ 6.
Evaluation of prostatectomy specimens
Prostatectomy specimens obtained through 127 open
retropubic surgery (74.7%) and 43 through robot-
assisted surgery (25.3%) were processed according to the
Stanford protocol [18], step sectioned transversely at
5 mm intervals, and mounted as half or quarter sections
for microscopic evaluation. Those were evaluated for
GS, extraprostatic extension, surgical margin status,
seminal vesicle invasion, lymph node involvement when
dissection was performed, and tumor volume. Gleason
scoring was also done as recommended in the ISUP
Consensus 2005 [16]. Prostate cancer volume was calcu-
lated from the three-dimensional measurements of thedominant nodule (index tumor) that correlates with
oncological outcome better than total tumor volume
[19], using a spherical formula and correcting by shrink-
age factor (1.33) due to formalin fixation. Two specialists
of urologic pathology from the 2 institutions reported
the histopathology of biopsy and prostatectomy speci-
mens, and we retrospectively reviewed the reports.
Definitions
To avoid confusion of terminology, we describe the fol-
lowing definitions. Classical insignificant cancer was de-
fined by a pathologic stage ≤ pT2, GS ≤ 6, and an index
tumor volume < 0.5 mL [8]. Redefined insignificant can-
cer was characterized as a pathologic stage ≤ pT2, GS ≤
6, and an updated index tumor volume threshold of
1.3 mL [13]. Both insignificant cancers are results con-
firmed on prostatectomy specimens. In addition, Epstein
criteria and PRIAS criteria are established sets of pre-
operative factors to predict insignificant cancer [10,17].
Biochemical recurrence was defined as PSA level greater
than 0.2 ng/mL with subsequent PSA rising.
Analyses and statistics
The associations between preoperative clinical data and
pathologic characteristics of prostatectomy specimens for
targeting the unfavorable pathologic results, and onco-
logical outcome were analyzed. The quantitative data were
categorized into two groups by median values, and the
qualitative data were compared using a chi-squared test or
Fisher’s exact test. Recurrence-free survival was estimated
using the Kaplan–Meier method and differences were
compared with the log-rank test. Logistic regression and
Cox proportional hazards regression model were used for
multivariate analyses. All statistical analyses were per-
formed with EZR, which is a graphical user interface for R
(The R Foundation for Statistical Computing, version
2.13.0). All statistical tests were two-sided, with p-value of
less than 0.05 considered to be statistically significant.
Ethics statement
This study was conducted in accordance with the Helsinki
Declaration and was approved by the institutional ethical
review boards at Dokkyo Medical University Hospital and
St. Luke’s International Hospital. In addition, each patient
signed a consent form with regard to the storage of their
information for the purpose of research.
Results
Tumor characteristics of prostatectomy specimens are
provided in Table 2. Pathologic stage ≥ pT3, positive sur-
gical margin (PSM), upgraded GS, index tumor volume ≥
0.5 mL, and ≥ 1.3 mL were detected in 25 patients
(14.7%), 29 patients (17.1%), 77 patients (45.3%), 83 pa-
tients (48.8%), and 53 patients (31.2%), respectively. Less
Table 2 Tumor Characteristic of prostatectomy specimens


























Abbreviations: NA not available due to pT0.
Yashi et al. BMC Urology 2014, 14:43 Page 4 of 9
http://www.biomedcentral.com/1471-2490/14/43than half of cases had classical (41.2%) and redefined
(47.6%) insignificant cancer. Of those with stage ≥ pT3,
23 patients had extraprostatic extension, and 4 patients
had seminal vesicle invasion. No lymph node involve-
ment was observed among 158 patients (92.9%) who
underwent lymph node dissection that was limited in
the obturator areas. In 7 patients, pT0 cancers, namely
“vanishing cancer” in prostatectomy specimens were ob-
served. These cases were accounted as insignificant can-
cers for the following analysis.
Univariate analyses of preoperative factors revealed
that the MRI-estimated prostate volume, PSAD, biopsy
tumor length, MRI findings, contemporary Epstein cri-
teria, and PRIAS criteria were all or partly associated
with unfavorable pathologic results on prostatectomy
specimens (Table 3), and all factors were associated with
the presence of insignificant cancer of both definitions
(Table 4). Meanwhile patient age, PSA value, number of
biopsy cores or positive cores, biopsy Gleason score 5 or
6, difference in biopsy approach or institution, and clin-
ical T-stage determined by digital rectal examination didnot hold any associations with unfavorable pathologic
results. Multivariate model excluding the established
preoperative criteria such as Epstein and PRIAS criteria
showed that both large prostate volume (≥35.5 cc) and
short tumor length on biopsy (≤2.0 mm) showed inde-
pendent predictive value for both classical and redefined
insignificant cancer. PSAD showed independent value
for only redefined insignificant cancer (Table 4). Figure 1
shows the profiles of prostate volume distribution in re-
lation to the unfavorable pathologic features, and the pa-
tients with prostate volume larger than 43.3 cc never
presented with pathologic stage ≥ pT3, and rarely pre-
sented with PSM (only 2 cases).
During a median follow-up of 39.5 months (interquar-
tile range 17.3-58.0), 16 patients developed biochemical
recurrence. The estimated 5-year recurrence-free survival
and cancer-specific survival were 87.0% and 100%, re-
spectively. PSM was the only independent factor among
unfavorable pathologic results. Figure 2 shows the
Kaplan–Meier event curves for biochemical recurrence-
free survivals. The patients with redefined insignificant
cancers essentially did not relapse regardless of the sur-
gical margin status, but 2 cases (2.5%) without PSM re-
lapsed and consequently received salvage radiotherapy.
When statistics were limited in 70 patients who met
the contemporary Epstein criteria, the rate of stage ≥
pT3, PSM, upgraded GS, index tumor volume ≥ 1.3 mL,
and redefined insignificant cancer reduced to 10.0%,
7.1%, 31.4%, 18.6%, and 64.3%, respectively. In 103 pa-
tients who met criteria of the PRIAS study, those rates
were 11.7%, 12.6%, 36.9%, 23.3%, and 56.3%, respectively.
Furthermore, in 32 patients that were classified as inter-
mediate risk or more because of a PSA value > 10 ng/
mL, the rate of redefined insignificant cancer was 43.8%.Discussion
Our study demonstrated that prostate volume and biopsy
tumor length had independent value for predicting both
classical and redefined insignificant cancer, and PSAD
showed the independent value for only the redefined in-
significant cancer. The different statistics between classical
and redefined insignificant cancers in the multivariate
analysis might imply that PSAD possibly holds predictive
power in larger or aggressive tumors. Substantial overlaps
existed in cases with small prostate volume, but large
prostate volume firmly had high positive predictive value
for tumors of stage ≤ pT2 and negative surgical margins,
namely organ-confined cancers. We consider that the
finding that prostate volume is important does not simply
mirror many other studies showing that PSAD is import-
ant. Furthermore, clinical T-staging had little value, and
the multiparametric MRI would possibly add some diag-
nostic value if evaluation was performed in detail.
Table 3 Preoperative factors associated with unfavorable pathologic results on prostatectomy specimens
Factors pT-stage Surgical margin Gleason score Index tumor volume
≤pT2 ≥pT3 p-value neg posi p-value ≤6 ≥7 p-value <0.5 mL ≥0.5 mL p-value <1.3 mL ≥1.3 mL p-value
Prostate
volume (cc)
≥35.5 81 4 0.0004 79 6 0.0009 61 24 <0.0001 60 25 <0.0001 71 14 <0.0001
<35.5 64 21 62 23 32 53 27 58 46 39
PSA density
(ng/ml/cc)
<0.172 78 7 0.0228 78 7 0.0037 58 27 0.0007 56 29 0.0002 69 16 0.0008
≥0.172 67 18 63 22 35 50 31 54 48 37
Tumor length
(mm)
≤2.0 107 11 0.0045 102 16 0.0788 76 42 0.0002 74 44 <0.0001 88 30 0.0194
>2.0 38 14 39 13 17 35 13 39 29 23
MRI findings
Positive 99 14 0.2560 99 14 0.0305 69 44 0.0227 68 45 0.0011 83 30 0.0801
Negative 46 11 42 15 24 33 19 38 34 23
Epstein criteria
Yes 63 7 0.1880 65 5 0.0038 48 22 0.0029 49 21 <0.0001 57 13 0.0040
No 82 18 76 24 45 55 38 63 60 40
PRIAS criteria
Yes 91 21 0.1870 90 13 0.0633 65 38 0.0075 64 39 0.0005 79 24 0.0070
No 54 13 51 16 28 39 23 44 38 39
Abbreviations: neg negative, posi positive.
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sistently harbor unfavorable pathologic results on pros-
tatectomy specimens despite fulfilling the established
criteria developed in North America and Europe. Cer-
tainly, in our data, patients meeting Epstein and PRIAS
criteria harbored clinically significant cancer for one-
third and around half of cases, respectively. Oon et al.
speculated that the modification to Gleason scoring
might be associated with a reduced accuracy of Epstein
criteria, because distinct differences were observed in
validation studies between pre- and post-2005 [11,18]. In
addition, Wolters, et al. presented a recent analysis usingTable 4 Univariate and multivariate analyses of factors predic
Classical insignificant canc
Factors Univariate model Multivar
OR 95% CI p-value OR 95%
Prostate volume (≥35.5 vs.<35.5) 5.87 2.97-11.60 <0.0001 4.59 2.13-
PSA density (<0.172 vs. ≥0.172) 3.71 1.94-7.10 <0.0001 2.12 0.99-
Tumor length (≤2.0 vs. >2.0) 5.11 2.29-11.40 <0.0001 5.41 2.21-
MRI findings (neg vs. posi) 2.43 1.22-4.83 0.0148 2.13 0.95-
Epstein criteria (yes vs. no) 3.46 1.82-6.58 0.0002
PRIAS criteria (yes vs. no) 2.48 1.28-4.78 0.0068
Abbreviations: OR Odds ratio, 95% CI 95% confidence interval, neg negative, posi poa data set from a randomized screening trial that dem-
onstrated that clinically insignificant prostate cancer
may include GS 6, pT2 tumors with index tumor vol-
umes of up to 1.3 mL [13] instead of 0.5 mL, which had
been used as a threshold for around 20 years [20]. These
critical alterations suggest reconsideration of the current
methods used for risk assessment before definitive ther-
apy or AS. The established criteria consisting of clinical
T-staging by digital rectal examination or PSAD would
not be satisfactory for patients in this study, and the
clinical criteria should be compiled incorporating the
prostate size and biopsy length involved by cancer.ting classical and redefined insignificant cancer
er Redefined insignificant cancer
iate model Univariate model Multivariate model
CI p-value OR 95% CI p-value OR 95% CI p-value
9.90 0.0001 5.79 2.99-11.20 <0.0001 4.31 2.07-8.98 <0.0001
4.53 0.0533 3.74 1.98-7.06 <0.0001 2.11 1.01-4.40 0.0460
13.2 0.0001 3.57 1.75-7.27 0.0005 3.46 1.56-7.69 0.0023




Figure 1 Prostate volume distribution in relation to unfavorable pathologic results on prostatectomy specimens. The patients with
prostate volume larger than 43.3 cc never presented with pathologic stage≥ pT3, and rarely presented with PSM. Prostate volume ≥35.5 cc
predicted stage≤ pT2 (p = 0.0004) and negative surgical margins (p = 0.0009), namely organ-confined cancers.
Figure 2 Kaplan–Meier event curves presenting biochemical
recurrence-free survivals for clinically significant/insignificant
cancer with or without positive surgical margin. The patients
with redefined insignificant cancers (pathologic stage ≤ pT2, GS≤ 6,
and index tumor volume < 1.3 mL) essentially did not relapse
regardless of the surgical margin status (only 2 cases without PSM
relapsed).
Yashi et al. BMC Urology 2014, 14:43 Page 6 of 9
http://www.biomedcentral.com/1471-2490/14/43Prostate volume has been less often mentioned than
PSAD or PSA as a predictive factor despite that all of
these parameters held independent values [21]. PSAD is
a comprehensive parameter considering both serum PSA
and prostate size, but the value varies easily based on
the fluctuation of PSA. In that sense, prostate volume
estimated using MRI is a stable preoperative parameter
and the only tumor-unrelated factor in our analysis
model. Despite the variations of study design and
whether the prostate volume was estimated pre- or post-
operatively, small prostate volume is unanimously re-
ported with association between the poor oncological
outcomes in several studies. Freedland et al. reported that
more high-grade and more advanced cancers were de-
tected in men with smaller prostates along with lower
serum testosterone concentrations in a large population
ranging from clinical T1 to T3 cancers and suggested that
prostate size might be an important prognostic variable
that should be evaluated for use pre- and postoperatively
[22]. Tilki et al. and Chung et al. reported the associations
especially in relation to GS upgrading [21,23]. These
trends were also observed even when study populations
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highly selective criteria (T1c, PSA < 10 ng/mL, a single
positive biopsy, tumor length < 3 mm, and Gleason
score < 7) by Beauval et al. [25]. The prostate volume
would be directly affected by age and endocrine factors
[26], and the mean prostate size should be significantly
different between Japanese and Western populations even
after adjusting for differences in age, height, and weight
[27]. Although the median prostate volume was obviously
different between 35.5 cc in our study and more than 40
to 50 cc in the Western study, our study confirmed that
prostate volume retained its predictive ability for both
classical and redefined insignificant cancer in Japanese
men.
The percentage and length of cancer involvement in
biopsy core are also significant predictors, and have
already been incorporated in the major prediction
models before developing AS protocols [28]. Russo et al.
reported that inclusion of the percentage of cancer in-
volvement contributed to reducing the misclassification
in patients eligible for AS according to the PRIAS cri-
teria, which does not reference any cancer involvement
in the core [29]. Antonelli et al. used the updated defin-
ition of total tumor volume and determined its optimal
cutoff to be 20% for the diagnosis of insignificant cancer
using the receiver operating characteristic curve [30].
Freedland et al. reported the same threshold of 20% for
predicting PSA recurrence after prostatectomy [31]. We
agree with their strict threshold despite the fact that our
data were analyzed in terms of tumor length but not in
the percentage of tumor involvement, and we consider
the threshold of 50%, which is used in the many AS proto-
cols, to be too relaxed to avoid under-estimation of can-
cer. However, a more stringent threshold, namely minute
or microfocal cancer defined by ≤ 5% or ≤ 1 mm in a single
core, is not a guarantee of insignificant cancer [8].
The current established clinical criteria can-not eliminate
the risk of over- and under- estimation of cancer. A strin-
gent selection criteria excludes a considerable number of
patients who are willing to be managed by AS, even those
having potentially insignificant cancer, and therefore, well-
balanced criteria between sensitivity and specificity are re-
quired for patients. The implication of increasing the index
tumor volume threshold to 1.3 mL is that we should miss
small-volume cancer and set the AS protocols to be more
expanded. In the recent report of head-to-head comparison
of contemporary AS protocols, Iremashvili et al. revealed
that the PRIAS and University of Miami criteria demon-
strated the best balance between sensitivity and specificity
for insignificant prostate cancer among the existing AS pro-
tocols, and the contemporary Epstein criteria demonstrated
high specificity but low sensitivity for all end points [32].
Nevertheless, clinically significant cancer might not al-
ways progress, and some cases might remain indolentfor a substantial duration of time. A validation of AS
protocol should not be a surrogate endpoint, such as the
analysis of the pathologic results of prostatectomy speci-
mens, but should be a long-term outcome of a prospect-
ive cohort. According to the review of AS in the large
prospective series, approximately one-third of patients
were treated after a median surveillance of about
2.5 years because of histologic reclassification on biopsy
or a PSA doubling time of less than 3 years, while some
cases were treated with no evidence of progression [33].
The short- to mid-term estimated treatment-free sur-
vivals were reported as 62 to 72% at 5 years and at 43 to
62% at 10 years [34,35]. These data characterize AS as a
strategy for deferring treatment and justify it as an opti-
mal choice for patients with low-risk PCa that can
accept the confirmatory biopsy within 1 to 2 years and
the slight increased risk of late metastasis.
To develop a model to discriminate clinically indolent
from aggressive disease efficiently, advances in biochem-
ical markers replacing PSA or PSA derivatives such as
prostate cancer antigen 3 or transmembrane protease
serine 2 will be required in addition to the existing fac-
tors [36]. In addition, a more detailed analysis of multi-
parametric MRI, including number of lesions, lesion
suspicion, and lesion density (calculated as total lesion
volume/prostate volume) [37], and image-guided tar-
geted biopsy should play a positive role [38]. The current
study has some limitations; there is no control popula-
tion outside of Japan other than the published literature.
It is a retrospective study based on a relatively small Jap-
anese population, and the pathologic examination was
performed at 2 institutions. The median follow-up time
was also relatively short to determine oncological out-
comes. Thus, the results may not apply to the Western
population. Nonetheless, it is valuable to give insight
into ethnic differences, and these data provide useful in-
formation that could help predict insignificant cancer in
Japanese or Asian patients with favorable features on
needle biopsy. The findings of this study should be vali-
dated in a larger, independent dataset.Conclusions
The favorable features of biopsy often are followed by
adverse pathologic findings on prostatectomy specimens
despite fulfilling the established criteria. Large prostate
volume and short tumor length on biopsy remained as
independent predictors for classical and redefined insig-
nificant prostate cancer in Japanese patients with favor-
able pathologic features on needle biopsy. The clinical
criteria for risk assessment before definitive therapy or
AS should incorporate these factors to minimize under-
estimation of cancer in Japanese patients with low-risk
PCa.
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